Expectations trend
FY2028 · fiscal year ending 2028-06-30 · fmp
Rezolute, Inc. (RZLT)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$3.64-8.08%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RZLT yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
reduce EPS losses toward zero | A primary condition in Rezolute, Inc.'s published investment case. The stated target is EPS loss improves to better than -$0.63 in FY27. | Intact | EPS loss worsens beyond -$0.63 in FY27 | Diluted EPS: $-0.20 per share FY2026-Q4; GAAP. Published target: EPS loss improves to better than -$0.63 in FY27. Annual target cannot be compared with a quarterly or TTM observation. Sep 24, 2026-0.2 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2028 · fiscal year ending 2028-06-30 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making clinical-stage biotech story, not an established earnings compounder. The long-term thesis is in a watch state: both key programs have shown progress, but important study and regulatory outcomes remain unresolved.
The evidence snapshot provides no valuation level or clear account of what the market expects, so whether RZLT is cheap or expensive versus peers cannot be assessed. No priced-in fragility gates fired, but that does not settle the valuation question.
Near term, results carry meaningful execution risk: RZLT missed in September after an earlier miss, and the estimated chance of another miss is 52%. Over the multi-year view, upLIFT is fully enrolled and 7 of 8 participants met the responder criterion, while the FDA encouraged a pre-BLA meeting for ersodetug; however, topline results are pending and sunRIZE missed its primary endpoint. Fiscal 2026 R&D costs fell from fiscal 2025, but higher general and administrative costs make overall expense control mixed.
The main swing factors are topline results from upLIFT and whether the FDA path for ersodetug can advance despite the missed primary endpoint. Near-term sector support may persist if healthcare bellwethers keep reporting strong results, while weakening employment or weaker bellweller results could reduce that support.
For the next 1 to 3 years, the thesis depends on converting clinical and regulatory progress into clearer evidence of program success while managing costs. Confidence is low, and the clinical outcomes and near-term execution remain uncertain. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
management stability and insider confidence |
| Rezolute is developing therapies for rare diseases with insider buying showing confidence. |
| Intact |
| significant insider selling or management instability |
Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
grow revenue from rare disease therapies | Rezolute is developing therapies for rare diseases with insider buying showing confidence. | Intact | revenue falls below $2.3 million in FY27 | Revenue: $0 FY2026-Q4; GAAP. Published target: revenue reaches at least $2.3 million in FY27. Annual target cannot be compared with a quarterly or TTM observation. Sep 24, 20260 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.33 → $-0.52 · observed estimates
$0.07B → $0.05B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-07-25 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-07-26 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-07-27 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-07-28 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-07-29 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-07-30 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-07-31 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-01 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-02 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-03 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-04 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-05 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-06 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-08 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-09 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-10 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-12 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-13 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-14 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-15 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-16 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-17 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-18 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-19 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-20 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-21 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-22 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-23 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-24 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-25 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-26 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-27 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-28 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-29 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-30 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-08-31 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-01 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-02 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-03 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-04 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-05 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-06 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-07 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-08 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-09 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-10 | $-0.22 | $75,156,000 | 7 / 7 |
| 2026-09-11 | $-0.22 | $75,156,000 | 7 / 7 |
| 2026-09-12 | $-0.22 | $75,156,000 | 7 / 7 |
| 2026-09-13 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-14 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-15 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-16 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-17 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-18 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-19 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-20 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-21 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-22 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-23 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-24 | $-0.33 | $66,098,142 | 7 / 7 |
| 2026-09-25 | $-0.32 | $96,181,000 | 6 / 6 |
| 2026-09-26 | $-0.41 | $72,839,400 | 5 / 5 |
| 2026-09-27 | $-0.41 | $72,839,400 | 5 / 5 |
| 2026-09-28 | $-0.41 | $72,839,400 | 5 / 5 |
| 2026-09-29 | $-0.41 | $72,839,400 | 5 / 5 |
| 2026-09-30 | $-0.45 | $64,542,429 | 5 / 6 |
| 2026-10-01 | $-0.45 | $64,548,142 | 5 / 6 |
| 2026-10-02 | $-0.52 | $56,792,125 | 6 / 7 |
| 2026-10-03 | $-0.52 | $56,792,125 | 6 / 7 |
| 2026-10-04 | $-0.52 | $56,792,125 | 6 / 7 |
| 2026-10-05 | $-0.52 | $56,792,125 | 6 / 7 |
| 2026-10-06 | $-0.52 | $56,792,125 | 6 / 7 |
| 2026-10-07 | $-0.51 | $57,106,889 | 6 / 7 |
| 2026-10-08 | $-0.51 | $57,258,000 | 6 / 7 |
| 2026-10-09 | $-0.51 | $57,258,000 | 6 / 7 |
| 2026-10-10 | $-0.51 | $57,258,000 | 6 / 7 |
| 2026-10-11 | $-0.51 | $57,258,000 | 6 / 7 |
| 2026-10-12 | $-0.51 | $57,258,000 | 6 / 7 |
| 2026-10-13 | $-0.51 | $57,258,000 | 6 / 7 |
| 2026-10-14 | $-0.51 | $57,258,000 | 6 / 7 |
| 2026-10-15 | $-0.51 | $57,258,000 | 6 / 7 |
| 2026-10-16 | $-0.51 | $57,258,000 | 6 / 6 |
| 2026-10-17 | $-0.51 | $57,258,000 | 6 / 6 |
| 2026-10-18 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-19 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-20 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-21 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-22 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-23 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-24 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-25 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-26 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-27 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-28 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-29 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-30 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-10-31 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-11-01 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-11-02 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-11-03 | $-0.52 | $54,094,000 | 6 / 7 |
| 2026-11-04 | $-0.52 | $54,094,000 | 6 / 7 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 11 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 3 recorded
1 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.